Kimberly Murphy - 07 Jun 2022 Form 4 Insider Report for Clarus Therapeutics Holdings, Inc. (CRXT)

Role
Director
Signature
/s/ Steven A. Bourne, attorney-in-fact
Issuer symbol
CRXT
Transactions as of
07 Jun 2022
Transactions value $
$0
Form type
4
Filing time
09 Jun 2022, 20:04:31 UTC
Previous filing
27 May 2022
Next filing
24 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRXT Common Stock Award $0 +1,922 +50% $0 5,766 07 Jun 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRXT Stock Option (Right to Buy) Award $0 +4,805 $0 4,805 07 Jun 2022 Common Stock 4,805 $0.4339 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person was granted a Restricted Stock Unit under the Issuer's 2021 Stock Option and Incentive Plan (the "2021 Plan") for 1,922 shares on 06/07/2022, which vests in full at the earlier of June 7, 2023 or the next annual meeting subject to the Reporting Person having a service relationship as of each such vesting.
F2 These options were granted under the 2021 Plan and vest in full at the earlier of June 7, 2023 or the next annual meeting subject to the Reporting Person having a service relationship as of each such vesting.